GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 6th April, 2020 on account of Mahavir Jayanti.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1%
Fri, 22 Feb

GLENMARK PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

GLENMARK PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m22,03725,81325,550-1.0%15.9%
Other incomeRs m-2321,399-1,090-177.9%
TurnoverRs m21,80527,21224,460-10.1%12.2%
ExpensesRs m18,81021,41221,204-1.0%12.7%
Gross profitRs m3,2276,0734,347-28.4%34.7%
DepreciationRs m7548258310.8%10.2%
InterestRs m7058518854.0%25.6%
Profit before taxRs m1,5375,7961,540-73.4%0.2%
TaxRs m4891,656377-77.2%-23.0%
Profit after taxRs m1,0474,1401,163-71.9%11.1%
Gross profit margin%14.623.517.0
Effective tax rate%31.828.624.5
Net profit margin%4.815.24.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 15.9% on a year-on-year (YoY) basis. The expenses were up by 12.7% YoY during the same period.
  • The company's operating profit increased by 34.7% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 17.0% in 3QFY19 as against 14.6% in 3QFY18.
  • Depreciation charges increased by 10.2% and finance costs increased by 25.6% YoY, respectively.
  • Other income increased by 370.6% YoY during the quarter.
  • Net profit for the quarter increased by 11.1% YoY. Net profit margins during the quarter declined from 4.8% in 3QFY18 to 4.8% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 1.0% on a quarter-on-quarter (QoQ) basis. The expenses were down by 1.0% QoQ during the same period.
  • The company's operating profit declined by 28.4% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 17.0% in 3QFY19 as against 23.5% in 2QFY18.
  • Net profit for the quarter declined by 71.9% QoQ, while net profit margins declined from 15.2% in 2QFY18 to 4.8% in 3QFY19.

To see how GLENMARK PHARMA has performed over the last eight quarters, please visit here.

GLENMARK PHARMA Share Price Performance

Over the last one year, GLENMARK PHARMA share price has moved up from Rs 524.4 to Rs 593.7, registering a Gain of Rs 69.3 or around 13.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,571.8 (up 0.5%). Over the last one year it has moved down from 13,958.5 to 13,571.8, a gain of 387 points (down 2.8%).

Overall, the S&P BSE SENSEX is up 6.0% over the year.

Current Valuations

At the current price of Rs 593.7, the price to earnings (P/E) ratio of GLENMARK PHARMA stands at 17.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.1 times.

Equitymaster requests your view! Post a comment on "GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1%". Click here!

  

Related Views on News

TORRENT PHARMA Surges by 7%; BSE HEALTHCARE Index Up 3.3% (Market Updates)

Apr 3, 2020 | Updated on Apr 3, 2020

TORRENT PHARMA share price has surged by 7% and its current market price is Rs 2,106. The BSE HEALTHCARE is up by 3.3%. The top gainers in the BSE HEALTHCARE Index are TORRENT PHARMA (up 6.9%) and APOLLO HOSPITALS (up 7.3%). The top losers are BLISS GVS PHARMA (down 0.1%) and GSK PHARMA (down 0.5%).

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 3, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS